Delivery Order SPE2DB20D3101-SPE2DB23FRKR6
- Not listed
- This federal contract award is for the delivery of LYUMJEV 100 UNIT/ML VIAL 10ML pharmaceutical products to the Defense Logistics Agency (DLA), a defense agency. The $1,291.63 Firm Fixed Price delivery order was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, on August 5, 2024 with a performance period ending on August 6, 2024. The contract does not have a set-aside designation. Amerisourcebergen holds an Indefinite Delivery Contract (IDC) with the DLA Troop Support...
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of LYUMJEV 100 UNIT/ML VIAL 10ML. The contract, which has a firm fixed price of $1,032.09 and a period of performance through August 8, 2024, was not set aside for any specific business category. As a key supplier to various federal agencies, AmerisourceBergen holds several Indefinite Delivery Contracts (IDCs) with the DLA and the...
- This federal contract award to Amerisourcebergen Drug Corp, Corporate Office Division, was issued by the Defense Logistics Agency (DLA) Troop Support Medical for the delivery of Lyumjev 100 Unit/mL Vial 10mL, a pharmaceutical product. The award, valued at $1,296.36, is a delivery order contract with a firm fixed price. The contract has an ultimate completion date of September 18, 2024. Amerisourcebergen is a major supplier of pharmaceutical products and medical supplies to the U.S. federal...
- The Defense Logistics Agency awarded a $2,102.00 delivery order to AmerisourceBergen Drug Corp for Lyumjev 100 Unit/mL vials (10 mL) under a firm fixed-price contract. The award, issued on October 22, 2025, with an ultimate completion date of October 23, 2025, represents a non-set-aside competitive procurement. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a major pharmaceutical distributor and critical vendor for federal medical procurement, particularly...
- This federal contract award is a delivery order issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,485.96 firm-fixed-price contract is for the supply of LYUMJEV 100 UNIT/ML KWIKPEN 3ML, a medication used for diabetes management. The contract has a period of performance through March 5, 2025 and is not designated as a set-aside. AmerisourceBergen holds a significant $999,999,999 Indefinite...
- This is a firm fixed-price delivery order awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA). The contract is for the supply of LYUMJEV 200 UNIT/ML KWIKPEN 3ML, a diabetes treatment medication, with a ceiling value of $3,926.76 and a performance period through May 20, 2025. The contract is not set aside and is an open competition. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop...
- This is a $2,505.41 delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distribution company, to provide Lyumjev 100 unit/mL KwikPen 3mL, a prescription insulin product. The contract has a firm fixed price and a completion date of April 26, 2024. AmerisourceBergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued up to $999,999,999.00 through December 31, 2025, which serves as...
- The Defense Logistics Agency awarded a Delivery Order (DO) valued at $1,120.66 to AmerisourceBergen Drug Corp for LYUMJEV 100 Unit/ML Vial 10ML, a rapid-acting insulin medication used in diabetes treatment. This non-set-aside, competitively awarded contract features firm fixed price terms with an ultimate completion date of November 13, 2025. The order will be fulfilled from AmerisourceBergen's corporate office located in Conshohocken, Pennsylvania, where the company maintains its headquarters...
- The Defense Logistics Agency awarded a $800 delivery order to Amerisourcebergen Drug Corporation for LYUMJEV 100 unit/ml vials. As the prime contractor, Amerisourcebergen will deliver 10 ml vials of the diabetes medication to a facility in Conshohocken, Pennsylvania within a firm fixed price contract starting August 11th and concluding on the 14th of 2023. The Defense Logistics Agency utilizes contracts such as this to efficiently procure necessary medical supplies for the U.S. Department of...
- This federal contract award was made by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract, valued at $1,062.56, is for the delivery of LYUMJEV 100 UNIT/ML VIAL 10ML, a type of medication. This is a delivery order placed under a larger Indefinite Delivery Contract (IDC) between Cencora, Inc. and the DLA Troop Support Medical, valued at up to $999,999,999.00 and running through December 31, 2025. The IDC serves as...
- SPE2DB20D3101Indefinite Delivery Contract
- SPE2DB20D3101-SPE2DB23FRKR6Delivery Order
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The contract, valued at $2,773.57, is for the delivery of LYUMJEV 100 UNIT/ML VIAL 10ML, a prescription medication. The contract has a firm fixed price pricing type and an ultimate completion date of May 5, 2023. Amerisourcebergen Drug Corp is a for-profit organization registered in the System for Award Management (SAM.gov) and holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The company also maintains a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at $750,000 through May 2024, which covers similar medical products and prescription drugs. The contract award does not indicate any set-aside requirements, suggesting open competition. The contract supports the DLA's mission of providing essential medical supplies and pharmaceuticals to military treatment facilities, veterans' healthcare programs, and other federal medical institutions.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.8k | 5/4/23 |